Brief: Quanterix Q2 Net Income USD -30.013 Million

Quanterix

07/08/2025 21:22

Overview

Quanterix Q2 2025 revenue falls 29% yr/yr, net loss widens significantly

Company completed acquisition of Akoya Biosciences, aiming for cash flow breakeven by 2026

Alzheimer's Diagnostics revenues more than tripled yr/yr, despite market challenges

Outlook

Quanterix expects full-year 2025 revenue between $130 mln and $135 mln

Quanterix projects GAAP gross margin of 49% to 53% for 2025

Company aims for cash flow breakeven in 2026

Result Drivers

AKOYA COMBINATION - Quanterix cites combination with Akoya Biosciences as creating high-margin, high-throughput business

ALZHEIMER'S DIAGNOSTICS - Alzheimer's Diagnostics revenues more than tripled yr/yr, indicating strong demand

ACCELERATOR BUSINESS - Net increase in new customers despite smaller project sizes due to constrained biopharma budgets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$16.83 mln
Q2 Net Income
-$30.01 mln
Q2 Basic EPS
-$0.77
Q2 Gross Profit
$11.30 mln
Q2 Operating Expenses
$48.40 mln
Q2 Operating Income
-$37.10 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Quanterix Corp is $8.00, about 29.9% above its August 6 closing price of $5.61

Press Release: ID:nBw2nmH8Ra

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)